Lynch syndrome (LS) is characterized by familial clustering of early cancer development in various organs. One of the histologic characteristics of carcinomas associated with LS is prominent intratumoral and peritumoral lymphocytes. The relationship between LS and the rare lymphocyte-rich clear cell renal cell carcinoma (CRCC) has been not been studied. We compared lymphocyte-rich CRCC (N = 15) with CRCC with no or minimal lymphoid infiltration, occurring in young (<40 y of age) patients (N = 15) and in a control group of older (>62 y of age) patients (N = 5) with CRCC having conventional histologic features. All cases were analyzed histologically and immunohistochemically using antibodies against the mismatch repair (MMR) proteins MLH1, MSH2, MSH6, and PMS2. The mutational status of the Von Hippel-Lindau (VHL) gene was analyzed successfully in 25 cases. We found no case with complete absence of immunoreactivity for the MMR proteins/ enzymes studied in any of the groups. Hence, none of the RCCs with heavy lymphocytic infiltration displayed complete absence of protein expression of any of the MMR enzymes. We found mutation of the VHL gene in 2 of 8 tumors from group A, in 4 of 12 tumors from group B, and no mutation in the control group C. We conclude that this rare subset of renal neoplasms is not part of the spectrum of tumors seen in LS. The results of the VHL gene analysis are in concordance with published data on sporadic CRCCs.
L ynch syndrome (LS) is a hereditary cancer syndrome with autosomal-dominant inheritance due to germline mutations in 1 of the 4 genes encoding a subset of key DNA-repairing enzymes, the mismatch repair (MMR) genes, MLH1, MSH2, MSH6, or PMS2, 1-3 inactivation of MSH2 because of a deletion of the 3'exons of the TACSTD1 gene, 4 or germline methylation of the MLH1 promoter. 5, 6 LS is characterized by familial clustering of early cancer development in various organs. Defective MMR of DNA gives rise to a high frequency (85%) of tumors with a high degree of microsatellite instability (MSI-H), that is, the presence of expanded or contracted number of tandem repeat DNA sequences that occur throughout the genome. [7] [8] [9] Germline mutations of MMR genes and a somatic mutation in the corresponding allele which leads to an absence of gene expression can be detected by absent reactivity for the protein/enzyme on immunohistochemistry (IHC). 10, 11 In addition to mucinous and medullary histologies, colorectal carcinomas associated with MSI are associated with the presence of lymphoid infiltration within (tumor-infiltrating lymphocytes) and around ("Crohn-like" inflammatory response) the tumors. [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] Over the years, we have encountered a rare subset of renal cell carcinoma (RCC), which displays an intense lymphoid infiltration into the neoplastic tissue similar to that observed in LS. To date, RCCs have not been implicated as a manifestation of LS. However, to the best of our knowledge, there has been no systematic study that has dealt with this. We therefore undertook this study to investigate whether lymphocyte-rich RCCs display absence of expression of MMR enzymes on IHC and hence could be part of LS. by a dense lymphoid population were identified. Fifteen young patients ( <40 y) with RCC were identified from the same pool of patients. Five older patients with typical clear cell RCC (CRCC) were included as the control group. All slides were retrieved and reviewed by the first and the last author (F.P. and O.H.).
Five cases were excluded from the study because of absent clinical data (1 case) or technical problems during the IHC study (4 cases). Altogether, 15 cases of RCCs with heavy lymphoid stroma were further studied. Tissue for light microscopy had been fixed in 10% buffered formalin, embedded in paraffin using routine procedures. Thin sections measuring 4 mm were cut and stained with hematoxylin and eosin.
IHC
The primary monoclonal antibodies listed below were used: MLH1 (G168-728, 1:25, Cell Marque Corporation, Rocklin, CA), MSH2 (G219-1129, 1:50, Cell Marque Corporation, Rocklin, CA), MSH6 (44, 1:20, Cell Marque Corporation, Rocklin, CA), and PMS2 (MRQ-28, 1:10, Cell Marque Corporation, Rocklin, CA). The primary antibodies were visualized using the supersensitive streptavidin-biotin-peroxidase complex (Biogenex, San Ramon, CA). Appropriate positive controls were used.
Analysis of the VHL Gene
For molecular genetic analysis, 36 formalin-fixed, paraffin-embedded tissue blocks were available. 10 micron thick sections were cut from each block. The neoplastic component was microdissected and DNA was extracted with the NucleoSpin Tissue Kit (Macherey Nagel, Duren, Germany) according to the manufacturer's protocol. Polymerase chain reaction (PCR) for Von Hippel-Lindau (VHL) gene analysis was carried out using the primers given in Table 1 . The reaction conditions were as follows: 12.5 mL of HotStar Taq PCR Master Mix (QIAgen, Hilden, Germany), 10 pmol of each primer, 100 ng of template DNA, and distilled water up to 25 mL. Amplification program for all fragments consisted of denaturation at 951C for 15 minutes, then 40 cycles of denaturation at 951C for 1 minute, annealing at 551C for 1 minute, and extension at 721C for 1 minute. The program was finished by incubation at 721C for 7 minutes.
Successfully amplified PCR products of the VHL gene were purified and sequenced using the BigDye Terminator Sequencing kit (PE/Applied Biosystems, Foster City, CA). Samples were then run on an automated sequencer ABI Prism 3130xl (PE/Applied Biosystems).
RESULTS
Basic clinicopathologic data for (A) the group of patients with lymphocyte-rich RCC, (B) the group of young patients with RCC, and (C) the group of older patients with RCC are summarized in Tables 1 to 4, respectively.
In brief, in group A, there were 6 men and 9 women. The median age was 57 years (range: 41 to 99 y). The median size of the tumors was 5.5 cm, mean 7.3 cm (range: 2.5 to 20 cm). All the tumors in group A were scored to have 3+ on the amount of lymphoid stroma ( Fig. 1 ). All but 1 patient in group A had CRCC, 1 patient had a papillary RCC (PRCC; type 2 according to Delahunt and Eble) 23 (Fig. 2) . None of the patients in group A had any history of neoplastic disease, no concurrent tumors, and no subsequent tumor development in any organ during follow-up. The architectural features of these CRCCs were consistent with usual CRCC. However, in addition, all tumors showed dense lymphoid infiltration. The lymphocytic infiltrate was present in thick streams resembling septae and/or was present diffusely within and throughout the neoplastic epithelial cell population (Figs. 3A, B ). The tumorous cells, featured clear to granular cytoplasm and the nuclear grade according to Fuhrman was 2 to 3 ( Fig. 4 ). Group B contained 7 men and 8 women. The median age was 34 years (range: 24 to 40 y) and the median size of the tumors was 3.5 cm, mean 5 cm (range 1.3 to 14.5 cm). A total of 12 of 16 tumors (from 15 patients) in group B were scored to have mild (1+) lymphoid infiltration in the tumors. The remaining tumors did not display any lymphoid infiltration. One patient had 2 (ipsilateral) renal tumors (patient number 9). Except for 3 cases, all tumors were typical CRCCs. One patient had a CRCC with a focus of PRCC, type 1 (of diameter more than 1 cm), 1 patient had a multicystic CRCC, and 1 patient had a PRCC that could not be further classified according to the criteria of Delahunt and Eble. 23 No patient in group B had any history of neoplastic disease. In 1 patient (patient number 9), a second tumor in the ipsilateral kidney was diagnosed during follow-up (1 y after resection of the first CRCC). Moreover, the second tumor was a typical CRCC. The same patient subsequently developed a cerebral oligodendroglioma.
In group C, there were 4 men and 1 woman, the median age was 65 years (range: 62 to 68 y). All patients had 1 renal tumor, all of which were CRCC. The median size of the tumors was 6.5 cm, with a mean of 6.3 cm (range: 1.8 to 12 cm). None of the tumors showed any lymphoid 
stroma. None of the patients in group C had any history of neoplastic disease, no concurrent tumors, and no subsequent tumor development during follow-up was observed.
IHC
The data from the immunohistochemical study is summarized in Tables 5 to 7, respectively (Figs. 5A-D). We found no case with complete absence of immunoreactivity for the MMR proteins studied in any of the groups. Hence, none of the RCCs with heavy lymphoid stroma showed complete absence of protein expression of any of the MMR enzymes on IHC. The extent of positivity varied significantly from tumors in which almost all neoplastic cells were positive to cases in which less than 10% of tumor cells showed nuclear immunoractivity. In fact, tumors with less than 10% cells were frequently seen. This was most commonly encountered for MLH1, MSH2, and MSH6 (the latter being most common) and most rarely for PMS2 (only 4 cases). We found no differences in the protein expression between groups A and B.
Results of the molecular genetic study are summarized in Tables 8 to 10 . DNA was successfully analyzed in 25 cases. In 11 tumors, the quality of DNA was not adequate for performing mutation analysis of the VHL gene. In the remaining cases, the whole coding sequences including exon-intron junctions of the VHL gene were obtained. Somatic mutation of the VHL gene was found in 5 tumors. Amino acid substitution was found in 3 tumors (Fig. 6A) . In 1 tumor, deletion of 2 amino acids was detected and 1 tumor had a shift mutation causing the formation of a premature stop codon (Fig. 6B ). In 1 case, a nonpathogenic mutation p.P25L was detected.
DISCUSSION
LS is an autosomal-dominant hereditary cancer syndrome first documented by A.S. Warthin in 1913 by pedigree analysis of the cancer family "G." 24, 25 Henry T. Lynch after whom this syndrome is named, also based on pedigree analysis, studied 2 "large midwestern kindreds" (1966) with the salient features of LS. 26 It was not until 1993 to 1994 that the molecular mechanisms behind LS was starting to become elucidated by Peltomaki et al and Aaltonen et al, 7, [27] [28] [29] who linked families with LS to a locus on chromosome 2p. By the end of 1993, the MSH2 gene on chromosome 2p had been cloned and germline mutations were found in families with LS. 27, 30 Soon, an additional germline mutation of the MLH1 gene on chromosome 3p was identified in families with LS. [31] [32] [33] Since then, it has been established that LS also may be caused by germline mutations (insertions, deletions, and missense mutations) in the MMR genes MSH6 and PMS2, [34] [35] [36] inactivation of MSH2 because of a deletion of the 3'exons of the TACSTD1 gene, 4 or because of germline methylation of the MLH1 promoter. 5, 6 The genetic basis for LS is complex and is not fully elucidated. This is highlighted in the recent World Health Organization edition on classification of tumors of the digestive system, 37 which states: "Patients without an identified germline defect in a DNA MMR gene, but with a tumor showing MSI and absence of immunohistochemical expression of the MMR proteins are very likely to have LS if other causes of MSI, such as methylation of the MLH1 promoter is excluded." LS manifests itself by familial clustering of early (on average 1 to 2 decades earlier than the nonsyndromic tumors), cancer development in the colorectum, endometrium, and to a lesser extent stomach, small bowel, bile ducts, ovaries, urinary tract (ureter and renal pelvis), brain (glioblastoma multiforme; the Turcot variant), and sebaceous neoplasms (the Muir-Torre variant). [38] [39] [40] [41] [42] [43] Urothelial carcinoma of the upper urinary tract is the most frequent urologic malignancy in patients with LS. [44] [45] [46] [47] As urothelial carcinoma of the renal pelvis may share overlapping histologic and/or radiologic features with CRCC, the pathologist should be cognizant of the possibility of LS, especially when confronted with fineneedle aspiration specimens or corebiopsy specimens from a young patient with a "renal mass."
It should be noted that Turcot syndrome shares genetic features of both LS and familial adenomatosis polyposis. 43 In addition to mucinous and medullary histologies, colorectal carcinomas associated with LS are frequently associated with the presence of lymphoid infiltration within (tumor-infiltrating lymphocytes) and around (Crohn-like inflammatory response) the tumors. [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] Defective MMR of DNA gives rise to a high frequency (85%) of tumors with a high degree of microsatellite instability, that is, the presence of expanded or contracted number of tandemly repeated DNA sequences that occur throughout the genome. [7] [8] [9] The gold standard method for detecting MSI is PCR analysis. However, as it is germline mutations in MMR genes in conjunction with somatic mutation in the corresponding allele which are at the core of the pathogenesis of the tumor diathesis in LS, and as these mutations will lead to silencing of its expression, this should, at least in theory, be detectable by absence of reactivity for the protein/enzyme on IHC. 10, 11 The early studies on IHC in LS focused on MSH2 and MLH1. 10, 48, 49 Although this methodology seemed to work for MLH2 mutations, the sensitivity of IHC in predicting MLH1 mutation was low. 50, 51 It has been suggested that some mutations in the MLH1 gene may be associated with a less than complete silencing of its expression. [52] [53] [54] However, based on the fact that MMR proteins form functional heterodimers (MSH1 with PMS2), adding anti-PMS2 identified 23% more patients with an MLH1 mutation in a study by de Jong et al. 55 The reason behind this phenomenon is that the mutated MLH1 that is expressed is defective such that it cannot adequately heterodimerize with PMS2 and the heterodimers become unstable leading to degradation of PMS2. [56] [57] [58] Furthermore, MSH2 dimerizes with MSH6 and the same reasoning applies to these complexes. MLH2 and MSH1 are regarded as "obligatory proteins" and MSH6 and PMS2 as "secondary proteins." Generally, defective obligatory proteins lead to degradation of the heterodimers with loss of both obligatory and secondary proteins. However, the reciprocal is not valid, that is, the presence of defects in secondary proteins (MSH6 and PMS2), the heterodimers may remain stable. This is because of the fact that other proteins such as MSH3, MLH3, and PMS1 may compensate for the defective secondary proteins MSH6 and PMS2. The implication of this for our study is that all 4 proteins need to be included to draw any conclusions.
Given the fact that we did not observe any tumors with complete absence of expression of the MMR enzymes MLH1, MSH2, MSH6, and PMS2 in our cohort of lymphocyte-rich RCC, in conjunction with that we could find no clinical evidence (eg, absence of family history and absence of multiple tumors), we conclude that none of these patients had LS. In concert with our findings, Kanomata et al 59 could not establish MSI in 45 cases of RCC occurring in young (<45 y) patients. As we only analyzed the VHL gene for substitutions and small deletions, other mechanism affecting the VHL gene and its expression such as large rearrangements of promoter methylation are not excluded. However, we found mutations in the VHL gene in 2 of 8 (25%) successfully analyzed tumors from group A, in 4 of 12 (33.3%) tumors from group B, and no mutations in control group C. These findings are in accordance with earlier published data with reported frequencies of 34% to 56% of VHL gene mutations in sporadic CRCC. 44 Hence, it seems that the lymphocyte-rich variant of CRCC does not differ significantly from classic CRCC regarding the frequency of mutations in the VHL gene.
We conclude that this rare subset of renal neoplasms is not part of the spectrum of tumors observed in LS. Furthermore, for the same reasons, the occurrence of RCC in young patients (below the age of 40 y) seems not to be associated with LS. However, immunohistochemical investigation for MMR enzymes may be technically challenging and in the right setting, clinicopathologic correlation and molecular genetic investigations are critically important if there is suspicion of LS, for example, positive family history of cancer, early age at tumor presentation, and/or histologic features of a carcinoma that points toward the possibility of LS. Importantly, one should bear in mind that the genetic basis of LS is complex and not yet fully elucidated.
